January 24, 2019 09:54 AM EST
Pharma

Ver­tex sharp­ens fo­cus on gene-edit­ing in li­cens­ing deal with Mer­ck KGaA

Natalie Grover

Reporter

Two years ago Mer­ck KGaA splurged $230 mil­lion to li­cense all the rights to four on­col­o­gy pro­grams, in­clud­ing a DNA-de­pen­dent pro­tein ki­nase (DNA-PK) in­hibitor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

A service from the Financial Times